Trial Profile
A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Amlodipine/rosuvastatin (Primary) ; Amlodipine; Rosuvastatin
- Indications Hyperlipidaemia; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Yuhan
- 31 Jan 2020 Primary endpoint Change of mean seated Systolic Blood Pressure has been met as per results published in the Journal of Clinical Hypertension (Greenwich)
- 31 Jan 2020 Primary endpoint, Percent change of LDL-Cholesterol, has been met as per results published in the Journal of Clinical Hypertension (Greenwich)
- 31 Jan 2020 Results published in the Journal of Clinical Hypertension (Greenwich)